Trial Profile

An observational, multi centre, Italian, retrospective, real World evidence cohort study describing one and two year Annualized Relapse Rate (ARR) and proportion of patients with No Evidene of Disease Activity (NEDA-3) in patients treated with Fingolimod

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2018 Preliminary results (n=391) assessing Annualized Relapse rate (ARR) and the proportion of patients with No Evidence of Disease Activity (NEDA-3) after 1 and 2 years of treatment, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
24 May 2018 New trial record
23 May 2018 Preliminary results (n=391) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com